Condition: Lymphoblastic Leukemia · Sponsor: Tanja Andrea Gruber
The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia cells outer membrane.
This description comes directly from the study's public registry record.
Tanja A Gruber, MD, PhD · 650 723 5535 · tagruber@stanford.edu
Always discuss trial participation with your own doctor first.
| Phoenix Children's Hospital | Phoenix, Arizona, United States | Recruiting |
| Arkansas Children's Hospital | Little Rock, Arkansas, United States | Recruiting |
| Children's Hospital Los Angeles | Los Angeles, California, United States | Recruiting |
| Valley Children's Hospital | Madera, California, United States | Recruiting |
| Children's Hospital of Orange County | Orange, California, United States | Recruiting |
| Stanford University | Palo Alto, California, United States | Recruiting |
| Rady Children's Hospital San Diego | San Diego, California, United States | Not Yet Recruiting |
| Arnold Palmer Hospital for Children | Orlando, Florida, United States | Recruiting |
| Children's Hospital of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Novant Health - Hemby Children's Hospital | Charlotte, North Carolina, United States | Not Yet Recruiting |
| Doernbecher Children's Hospital | Portland, Oregon, United States | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05848687